BridgeBio Pharma SG&A Expenses 2018-2024 | BBIO

BridgeBio Pharma sg&a expenses for the twelve months ending December 31, 2024 were $0.289B, a 91.87% increase year-over-year.

  • BridgeBio Pharma annual sg&a expenses for 2023 were $0.151B, a 5.17% increase from 2022.
  • BridgeBio Pharma annual sg&a expenses for 2022 were $0.143B, a 25.5% decline from 2021.
  • BridgeBio Pharma annual sg&a expenses for 2021 were $0.192B, a 31.94% increase from 2020.

BridgeBio Pharma SG&A Expenses 2018-2024 | BBIO

  • BridgeBio Pharma annual sg&a expenses for 2023 were $0.151B, a 5.17% increase from 2022.
  • BridgeBio Pharma annual sg&a expenses for 2022 were $0.143B, a 25.5% decline from 2021.
  • BridgeBio Pharma annual sg&a expenses for 2021 were $0.192B, a 31.94% increase from 2020.
Related Stocks
Company NameMarket
Cap
Teva Pharmaceutical Industries (TEVA)$19.4B
Dr Reddy's Laboratories (RDY)$11.2B
Bausch Health Cos (BHC)$2.4B
Supernus Pharmaceuticals (SUPN)$1.9B
Amphastar Pharmaceuticals (AMPH)$1.5B
Personalis (PSNL)$412M
Taysha Gene Therapies (TSHA)$336M
Assembly Biosciences (ASMB)$81M
Sol-Gel Technologies (SLGL)$16M
Evoke Pharma (EVOK)$8M
Teligent (TLGT)$0M